Sökning: "PDAC"
Visar resultat 1 - 5 av 31 avhandlingar innehållade ordet PDAC.
1. Molecular mechanisms of nerve-tumor interactions : the intersection of cancer and neurodevelopment
Sammanfattning : A wide range of cancers throughout the body are characterized by high nerve density and invasion of cancer cells within the nerves, a process called perineural invasion (PNI). Work in the field has shown that blocking nerves in organs with tumors leads to improved disease outcomes suggesting that finding ways to block tumor nerves could lead to new treatment approaches. LÄS MER
2. The identification and functional evaluation of novel cancer-associated fibroblast subtypes and matrisome proteins in pancreatic cancer
Sammanfattning : Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy characterized by an extensive desmoplastic stroma. The stroma is the site of intricate communication between malignant cells and their surrounding environment. LÄS MER
3. Utilizing Biopolymers in 3D Tumor Modeling and Tumor Diagnosis
Sammanfattning : Cancer represents a significant global public health challenge and ranks as the second mostcommon cause of death in the United States. The onset of cancer entails an initial phasewhere cells lose their polarity and disconnect from the normal basement membrane, allowingthem to form distinct three-dimensional (3D) configurations that interact with adjacent cellsand the surrounding microenvironment. LÄS MER
4. Stromal components and micro-RNAs as biomarkers in pancreatic cancer
Sammanfattning : Background Pancreatic ductal adenocarcinoma (PDAC) patients have the poorest 5-year survival rates of all cancer forms. It is difficult to diagnose at early disease stages, tumour relapse after surgery is common, and current chemotherapies are ineffective. LÄS MER
5. Immunosuppressive and metastasis-promoting matrisome proteins in pancreatic cancer : the role of galectin 4 and SERPINB5
Sammanfattning : In Sweden 1200-1300 people are diagnosed with pancreatic ductal adenocarcinoma (PDAC) every year. Late diagnosis, together with poor treatment response and resistance to checkpoint inhibitor immunotherapy, contributes to the poor prognosis of the disease. LÄS MER